Why the study?
Does propofol reduce mean arterial pressure and systemic vascular resistance during cardiopulmonary bypass in patients undergoing cardiac surgery?
Does propofol reduce mean arterial pressure and systemic vascular resistance during cardiopulmonary bypass in patients undergoing cardiac surgery?
A bolus injection of propofol during cardiopulmonary bypass causes hypotension, which is mediated at least in part by a direct decrease in systemic vascular resistance.
Propofol boluses during CPB warrant caution for hypotension; confirms direct SVR reduction as the mechanism in cardiac surgery.
This study was designed to evaluate the effects of propofol on mean arterial pressure (MAP) and systemic vascular resistance (SVR) during cardiopulmonary bypass (CPB). Twenty patients were divided randomly for administration of 2 mg.kg-1 propofol (group Propofol, n = 10) or 0.9% saline solution (group Control, n = 10) during CPB. The two groups were comparable with respect to sex, age, height, type of surgery (valvular or coronary), arterial hypertension and preoperative antihypertensive treatment. Only their weight and body surface area were significantly different (control group vs propofol group, respectively: 78.5 +/- 14.4 vs 64.7 +/- 7.7 kg, P < 0.05; and 1.85 +/- 0.2 vs 1.68 +/- 0.13 m2, P < 0.05). MAP, SVR and SVR index were significantly lower in the propofol group than in the control group at 10, 15 and 20 min of study, suggesting that the hypotensive effect of a bolus injection of propofol is due, at least in part, to a direct decrease in the SVR.
No takes yet. Share an insight, caveat, or question.
Pensado et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: